The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium]
stearic acid results in decreased expression of ADIPOQ mRNA resveratrol inhibits the reaction [stearic acid results in decreased expression of ADIPOQ mRNA]
ALB protein binds to stearic acid; stearic acid binds to ALB protein [[[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine] which affects the activity of ALB protein; [[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine; [ALB protein binds to stearic acid] promotes the reaction [ALB protein results in increased reduction of Dithionitrobenzoic Acid]; [ALB protein binds to stearic acid] promotes the reaction [Pyruvaldehyde results in increased oxidation of ALB protein]; [ALB protein modified form binds to stearic acid] which results in decreased reduction of Dithionitrobenzoic Acid; [stearic acid binds to ALB protein] which affects the susceptibility to Clozapine; stearic acid inhibits the reaction [Clozapine binds to ALB protein]; stearic acid inhibits the reaction [ziprasidone binds to ALB protein]
SCD1 protein inhibits the reaction [stearic acid results in increased activity of CASP3 protein]; stearic acid results in increased cleavage of and results in increased activity of CASP3 protein
stearic acid results in increased expression of CSF2 mRNA [CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate
INS protein inhibits the reaction [stearic acid results in decreased expression of CYP3A4 mRNA] stearic acid results in decreased expression of CYP3A4 mRNA; stearic acid results in decreased expression of CYP3A4 protein
INS protein inhibits the reaction [stearic acid results in decreased expression of CYP3A4 mRNA]; INS protein inhibits the reaction [stearic acid results in increased chemical synthesis of 6-hydroxychlorzoxazone]; INS protein inhibits the reaction [stearic acid results in increased hydroxylation of Chlorzoxazone] [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of stearic acid analog; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of stearic acid analog
SCD1 protein inhibits the reaction [stearic acid results in increased abundance of Ceramides]; SCD1 protein inhibits the reaction [stearic acid results in increased abundance of Reactive Oxygen Species]; SCD1 protein inhibits the reaction [stearic acid results in increased activity of CASP3 protein] SCD1 protein results in decreased susceptibility to stearic acid stearic acid results in increased expression of SCD1 mRNA
[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein
[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein] [perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein perifosine results in decreased phosphorylation of AKT1 protein
[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein
[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein
[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein perifosine results in decreased expression of CASP3 protein
[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]
[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein
perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]
[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]
ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form] LAT2 protein results in decreased susceptibility to perifosine
MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]
[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein
[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein
[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]
perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]
Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]
browse the term
